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Abstract
OBJECTIVE: To study the clinical curative effect,
safety and mechanism of action of electroacupunc-
ture combined with Zhizhukuanzhong capsules
(ZZKZC) in treating gastroesophageal reflux dis-
ease (GERD).
METHODS: A total of 480 patients with confirmed
GERD were randomly divided into four groups: the
electroacupuncture group, the ZZKZC group, the
combined therapy group, and the control group,
with 120 cases in each group. Each case in the elec-
troacupuncture group was treated with electroacu-
puncture on Zusanli (ST 36), Zhongwan (CV 12), Nei-
guan (PC 6),Taichong (LR 3) andGongsun (SP 4) once
daily for 6 weeks. Each case in the ZZKZC group was
treated with oral administration of 1.29 g ZZKZC
three times daily. The combined therapy group had
electroacupuncture and ZZKZC. The control group
was given oral administration of 5 mg mosapride
three times and 20 mg pantoprazole twice daily.
The 24-hour intraesophageal total number of reflux
episodes with pH <4 (or bilirubin absorbance ≥
0.14), the number of long-term (≥5 min) reflux epi-
sodes, the percentage of upright time, the percent-
age of supine time, the percentage of total time of
pH <4 (or bilirubin absorbance ≥0.14), endoscopic
grading score, symptom score, quality of life score,
and adverse reactions were observed before treat-
ment, at the end of treatment and 54 weeks after
treatment in the four groups.
RESULTS: The 24-hour intraesophageal pH and bile
reflux, endoscopic grading score and symptom
score were all significantly decreased at the end of
treatment in every group, while the scores of 8 di-
mensions of quality of life were all increased com-
pared with those before treatment (P<0.01). All of
these indices were better in the combined therapy
group than those in the other groups (P<0.05).
These indices did not significantly deteriorate in
the combined therapy group and electroacupunc-
ture group 54 weeks after treatment compared
with the end of treatment (P>0.05); however, these
indices all significantly deteriorated in the ZZKZC
and control groups (P>0.05). The short and
long-term total efficacy rates in the combined ther-
apy group showed significant superiority to those
in the other groups (P<0.05 or P<0.01). No serious
adverse reactions were found in the four groups.
CONCLUSION: Electroacupuncture and ZZKZC
play an important role in inhibiting intraesopha-
geal acid and bile reflux, decreasing the endoscop-
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ic grading score, and alleviating the symptoms of
gastroesophageal reflux to improve the quality of
life. However, the effect of combined treatment is
more effective, with better security and long-term
efficacy, and therefore, this combination treatment
is appropriate for clinical use.
© 2012 JTCM. All rights reserved.
Key words: Electroacupuncture; Zhizhukuanzhong
capsules; Gastroesophageal reflux; Bile reflux; Quali-
ty of life
INTRODUCTION
Gastroesophageal Reflux Disease (GERD) is a condi-
tion in which the gastroduodenal contents, including
gastric acid, bile, pancreatic juice, and pepsin, leak
backwards into the esophagus, which stimulate the
esophageal membrane repeatedly and injure the barri-
er.1 The incidence rate of reflux symptoms is greater
than 15% in the population, which severely affects the
quality of life. Long-term reflux may lead to esophageal
mucosa erosion, hemorrhage, stenosis, pharyngeal ul-
cer, and asthma.2,3 The abuse of related drugs may in-
duce many adverse effects.
In recent years, combined administration of proton
pump inhibitors and gastrointestinal prokinetic agents
in the treatment of GERD have achieved a certain ther-
apeutic effect, but they require a long therapeutic
course and it is a heavy economic burden on the pa-
tient, with a high recurrence rate after withdrawal of
the drugs. Clinically, integrated acupuncture and tradi-
tional Chinese medicine have satisfactory effects on
GERD, but there are few systematic reports on this
type of treatment.
In the current study, 480 cases of GERD were treated
with acupuncture and Zhizhukuanzhong capsules (ZZ-
KZC). We examined changes in intraesophageal acid
and bile reflux, endoscopic grading and symptom
scores, and adverse reactions before treatment (T1), at
the end of treatment (T2), and 54 weeks after treat-
ment (T3). Pantoprazole and mosapride were used as
controls. We aimed to examine the clinical long-term
efficacy and safety, and the therapeutic mechanism of
combining electroacupuncture and ZZKZC on
GERD.
METHODS
Diagnostic criteria
According to the literature,4 the diagnostic standard of
GERD were defined as follows: 1) patients who suf-
fered from a group of reflux symptoms, including the
main symptoms (heartburn, reverse flow, and acid re-
gurgitation), which can be accompanied by related
symptoms (e.g., noncardiac chest pain, upper abdomi-
nal pain or/and discomfort, belching, abdominal dis-
tension, foreign body sensation in the throat, odyno-
phagia, and dysphagia) and extra-esophageal symptoms
(e.g., chronic cough, pharyngolaryngitis, and asthma);
these symptoms were estimated using 6 scores by the
reflux disease questionnaire (RDQ); 2) an endoscopic
examination showed esophagitis that was involved the
distal part of the esophagus, but with no findings of
secondary esophagitis-inducing factors, such as diges-
tive ulcers, pyloric obstruction, and vomiting; the sever-
ity of the esophagitis was classified into five grades
from 0 to 4 according to the Los Angeles Grading
(LAG) method;5 3) 24-h monitoring of intraesopha-
geal pH showed overfull acid reflux; and 4) a proton
pump inhibitor test showed positive results. Those pa-
tients who were consistent with 1)+2), 1)+3), or 1)+4)
were diagnosed with GERD.
Inclusive criteria
We included the following: 1) patients aged between
17 to 68 years, male and/or female; 2) patients con-
firmed with the above-mentioned diagnostic criteria of
GERD; 3) secondary esophageal diseases were exclud-
ed by endoscope or upper digestive contrast examina-
tion within 1 month; and 4) patients voluntarily
signed the informed consent form. Medicines that
would affect the present study results, such as proton
pump inhibitors and gastro-intestinal dynamic agents,
were suspended 1 week prior to receiving the treatment.
Exclusive criteria
The following were excluded: 1) if it was confirmed by
examination that GERD-like symptoms were induced
by heart or lung diseases, tumors of the digestive tract,
drug-induced, mycotic and erosive esophagitis ,esopha-
geal disease due to immune dysfunction, post-cardioto-
my symptoms, cardiac achalasia, and pyloric obstruc-
tion; 2) pregnant women or those in the breast feeding
period; 3) patients who were allergic to test medicines;
4) patients who were complicated by severe primary
diseases, such as cardiovascular, hepatic, renal or hema-
topoietic system diseases, and those with mental diseas-
es.
General data
A total of 480 cases were all out-patients or in-patients
from the Department of Gastroenterology from Octo-
ber 2009 to October 2011. The patients were all defi-
nitely diagnosed with GERD and other local or gener-
al lesions were excluded after various relative examina-
tions.
The patients were randomly divided into four groups:
the electroacupuncture group, the ZZKZC group, the
combined therapy group (electroacupuncture + ZZ-
KZC), and the Western medicine group (control
group) chosen by random number table according to
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the visiting order. There were 120 cases in each group.
1) In the electroacupuncture group, 61 cases were male
and 59 were female, and they were aged from 18 to 62
years [mean, (43±9) years]. The duration of illness was
from 5 months to 11.0 years [mean, (5±4) years]. With
regard to the degree of lesions, 35 cases were mild
(grades 0-1 according to the LAG method), 42 were
moderate (grade 2) and 43 were severe (grades 3-4). 2)
In the ZZKZC group, 63 cases were male and 57 were
female, and they were aged from 18 to 61 years (mean,
43 ± 15 years). The duration of illness was from 6
months to 12.0 years [mean, (5±4) years]. With regard
to the degree of lesions, 36 cases were mild, 41 were
moderate, and 43 were severe. 3) In the combined ther-
apy group, 62 cases were male and 58 were female, and
they were aged from 17 to 61 years (mean, 41 ± 14
years). The duration of illness was from 5 months to
11.0 years [mean, (5±4) year]. With regard to the de-
gree of lesions, 37 cases were mild, 38 were moderate,
and 45 were severe. 4) In the control group, 60 cases
were male and 60 were female, and they were aged
from 18 to 60 years [mean, (42±13) years]. The dura-
tion of illness was between 7 months to 11.0 years
[mean, (5±4) years]. With regard to the degree of le-
sions, 39 cases were mild, 36 were moderate and 45
were severe. There were no significant differences in
sex, age and duration of illness among the four groups
(all P<0.05).
Treatment
Electroacupuncture group: We selected the following
points: Zusanli (ST 36), Zhongwan (CV 12), Neiguan
(PC 6), Taichong (LR 3) and Gongsun (SP 4). Patients
were placed in the dorsal position and the selected
points were routinely disinfected. Hwato brand needles
0.38 mm in diameter and 50-80 mm in length were ad-
opted. The operator held the needle with the right
hand, and the needle was inserted into the subcutane-
ous part of the body 35-65 mm deep at an angle of 90°
between the needle body and the skin. The needles
were then connected with a G6805 electroacupuncture
treatment instrument (Nanchang Gaoteng technology
limited company), at a frequency of 2 Hz/200 Hz, and
a current intensity that made the abdominal muscles of
the patient slightly vibrate as limitation. The needles
were retained for 15 min each time, twice daily, and
one therapeutic course consisted of one week with an
interval of 2 days between two courses. Treatment was
administered for 6 weeks.
The ZZKZC group: Zhizhukuanzhong capsules
(0.43 g/capsule) (Shanxi Shuangren Pharmaceutical
Co. Ltd., instrument of ratification No: Z20020003)
was orally administered to patients in the ZZKZC
group 30 min before meals at a dose of 1.29 g three
times a day for 6 weeks.
Combined therapy group: Patients in the combination
group were treated with both electroacupuncture and
Zhizhukuanzhong capsules, as described above.
Control group: Pantoprazole (20 mg/tablet) (Shenyang
Dongyu Pharmaceutical Co. Ltd., instrument of ratifi-
cation No: H20059067) was orally administered to pa-
tients 30 min before meals at a dose of 20 mg twice dai-
ly. In addition, mosapride (5 mg/tablet) (Lunan Beite
Pharmaceutical Co. Ltd., instrument of ratification
No: H19990317) was orally administered to patients
30 min before meals at a dose of 5 mg three times a
day. The treatment was given for 6 weeks.
Observation indices
Twenty-four-hour monitoring of intraesophageal acid
and bile reflux: Intraesophageal acid and bile reflux
were detected simultaneously by using the Digitrap-
perMK III type portable monitor for acid reflux and
the Bilitec 2000 monitor for bile reflux (Medtronic
Synectics Company, Sweden). Measurements were per-
formed in each patient at the three designed time
points during the observation period, i.e., before treat-
ment, at the end of treatment, and 54 weeks after treat-
ment. Patients were made to fast over night before mea-
surements. Catheterization was implemented at 8 a.m.
and kept in place for 24 h. On the day of measure-
ments, the patients were allowed to move and sleep
freely. However, strenuous exercise was avoided. The
duration in lying, moving, and having meals, and
symptoms occurring during the monitoring were re-
corded in detail. For 24-h monitoring of the intrae-
sophageal acid reflux,6 esophageal acid reflux was de-
tected by an electrode inserted into the esophagus,
and this electrode was previously calibrated in standard
buffer solutions with pH=1 and pH=7. The electrode
was inserted into the esophagus through the nasal cavi-
ty and positioned at the level of the lower esophageal
sphincter or 5 cm upper to the esophago-gastric junc-
tion by pH gradient or the scenographic method. The
electrode was fixed and connected to a pH monitor for
24 h. The acid reflux parameters tested were as follows:
1) the total number of reflux episodes with a pH <4; 2)
the number of long-term (5 min) reflux episodes with
a pH <4; 3) the percentage of upright time with a pH <
4; 4) the percentage of supine time with a pH <4; and
5) the percentage of total time with a pH <4. Patholog-
ical acid reflux was defined as the percentage of the to-
tal time with a pH <4 greater than 4.0%.
For 24-h monitoring of the intraesophageal bile reflux,7
esophageal bile reflux was detected by inserting a de-
tecting probe which was previously calibrated in
opaque bottled clean water and fixed at the same level
as that of the electrode inserted in the homolat nostril
for 24-h monitoring. The following parameters were
detected: 1) the total number of reflux episodes with a
bilirubin absorbance (Abs) ≥0.14; 2) the number of
long-term (≥5 min) reflux episodes with an Abs ≥0.14;
3) percentage of upright time with an Abs ≥0.14; 4)
the percentage of supine time with an Abs ≥0.14; and
5) the percentage of the total time with an Abs ≥0.14.
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Pathological bile reflux was defined as the percentage
of total time with an Abs ≥0.14 greater than 4.0%.
Esophageal mucosa in endoscopic examinations
Esophageal mucosa was observed under an Olympus
endoscope type GIF-XQ240 (Olympus Corporation,
Japan) at the three designed time points. Patients were
asked to fast from the last evening after 8:00 p.m. until
the examination was finished. The observed features
were graded and scored according to the LAG method,
i.e., grade 0 indicates no breakage of the esophageal
membrane, scored as 0; grade I indicates 1 or more
breakages with a maximum diameter ≤5 mm, scored as
1; grade II indicates 1 or more breakages, with a maxi-
mum diameter >5 mm, but without fused lesions;
grade III indicates fused damage on the membrane,
but with a size less than 75% of the esophageal circum-
ference, scored as 3; and grade IV indicates fused dam-
age that is greater than 75% of the esophageal circum-
ference, scored as 4.
Evaluation of reflux symptoms
The scores of the main reflux symptoms, including
heartburn, reverse flow, and acid regurgitation, were as-
sessed separately according to the severity and frequen-
cy. A total of 0-3 points were assessed according to the
degree of severity: a score of 0 indicated no symptoms;
a score of 1 indicated mild symptoms only when awak-
ing; a score of 2 indicated obvious subjective symp-
toms without affecting the patient's work and life; and
a score of 3 indicated severe symptoms that affected
the work and life of the patient. The sum of the scores
on the severity of the three symptoms constituted the
total score of symptom severity. A total of 0-3 points
were given according to symptom frequency: a score of
0 indicated no symptoms; a score of 1 indicated a low
frequency (≤3 times/week) of symptoms; a score of 2
indicated a moderate frequency (>3 but <7 times/
week) of symptoms; and a score of 3 indicated a high
frequency (>7 times/week) of symptoms. The product
of the total score of the severity and frequency of symp-
toms was calculated and regarded as the total symptom
score. It was measured at the designed three time
points (T1, T2, and T3).
Assessment of quality of life
We used the Short Form 36 Health Survey Question-
naires (SF-36),8 which includes 36 clauses, and 8 do-
mains of physical function (PF), role physical (RP),
role emotional (RE), social function (SF), mental
health (MH), vitality (VT), bodily pain (BP) and gen-
eral health (GH). The score scale ranges from 0 to 100,
and a higher score represents a better quality of life.
Assessment of curative effects
We calculated the short-term efficacy index as: (total
symptom score pre-treatment-total symptom score at
the end of treatment) ÷ total symptom score pre-treat-
ment×100%. The long-term efficacy index was calcu-
lated as: (total symptom score pre-treatment-total
symptom score 8 weeks post-treatment) ÷ total symp-
tom score pre-treatment × 100% . An efficacy index >
75% was regarded as marked efficacy, 51%-75% as effi-
cacy, 26%-50% as improvement, and ≤25% as ineffica-
cy.
Examinations
A physical examination, routine examination of blood,
urine, and stool, function of the liver and kidney, mea-
surement of electrolytes, and electrocardiogram were
carried out in patients in the four groups before treat-
ment, at the end of treatment and 54 weeks after treat-
ment.
Statistical analysis
The data were analyzed by SPSS13.0 software and ex-
pressed as mean±standard deviation ( xˉ ±s). The t-test
was used for comparison between two groups and P<
0.05 was regarded as a significant difference.
RESULTS
Comparison of 24-h intraesophageal pH and bile
reflux, symptom score, endoscopic grading score and
quality of life in the four groups
Twenty-four-hour intraesophageal pH and bile reflux,
and endoscopic grading and symptom scores were all
significantly decreased at T2 in every group, while the
scores of 8 dimensions of quality of life were all signifi-
cantly increased compared with those at T1 (P<0.01).
All of these indices were better in the combined thera-
py group than those in the other groups (P<0.05).
Twenty-four-hour intraesophageal pH and bile reflux,
endoscopic grading and symptom scores, and scores of
8 dimensions of quality of life did not significantly de-
teriorate in the combined therapy group or electroacu-
puncture group at T3 compared with those at T2 (P>
0.05), but these indices all significantly deteriorated in
the ZZKZC and control groups (P<0.05). All of these
indices in the electroacupuncture group at T3 were bet-
ter than those in the ZZKZC and control groups, and
these indices were better in the combined therapy
group than those in the other groups (P<0.05, P<0.01,
Tables 1-4).
Comparison of efficacy in the four groups
The short-term efficacy was better in the combined
therapy group than that in the other groups (all P<
0.05). The long-term efficacy was decreased in the
combined therapy and electroacupuncture groups com-
pared with the short-term efficacy, but this difference
was not significant (P>0.05). However, the long-term
efficacy was significantly decreased in the ZZKZC and
control groups compared with the short-term efficacy
(P<0.05). The long-term efficacy in the electroacu-
puncture group was better than that in the ZZKZC
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and control groups, and the long-term efficacy was bet-
ter in the combined therapy group than that in the oth-
er groups (P<0.05, P<0.01, Table 5).
Adverse reactions
In the control group, 3 cases had mild diarrhea at the
initial stage of treatment, with no special treatment,
and 5 days later it was spontaneously alleviated. There
were no adverse reactions in the other groups. Among
the four groups, there were no obvious changes in a
physical examination, blood, urine and stool routine
examination, liver and kidney function, electrolytes, co-
lon microscopy and electrocardiogram.
Table 1 Comparison of acid reflux at T1, T2 and T3 in the four groups ( xˉ ±s)
Groups
Combined
therapy
group
Electroacup
uncture
group
ZZKZC
group
Control
group
T
T1
T2
T3
T1
T2
T3
T1
T2
T3
T1
T2
T3
n
120
120
120
120
120
120
120
120
120
120
120
120
Total times of
reflux
92±44
33±30abc
34±26defg
92±64
47±32ah
47±22di
92±54
47±12ah
60±25ik
92±44
47±42a
60±26j
Times of long-
term reflux
13±5
5±4abc
5±3defg
13±5
7±5ah
7±3di
13±3
7±5ah
9±3jk
13±6
7±6a
9±6j
Percentage of
upright time with
pH<4
23±9
8±4abc
9±3defg
23±5
12±6ah
12±6di
23±8
12±4ah
16±6jk
23±10
12±7a
16±8j
Percentage of
supine time with
pH<4
15±5
6±3bc
6±3defg
15±8
8±86h
8±4di
15±8
8±5ah
11±6jk
15±3
8±5a
11±4j
Percentage of
total time with
pH<4
18±9
7±5abc
7±6defg
18±8
10±8ah
10±10di
18±12
10±9ah
14±11jk
18±6
10±7a
14±11j
Notes: Compared with the same group at T1,aP<0.01; Compared with control group at T2, bP<0.05, hP>0.05; Compared with
electroacupuncture or ZZKZC group at T2, cP<0.05; Compared with the same group at T2, dP>0.05, jP<0.05; Compared with control group
at T3, eP<0.01, iP<0.05, kP>0.05; Compared with electroacupuncture group at T3, fP<0.05; Compared with ZZKZC group at T3, gP<0.01.
Table 2 Comparison of bile reflux at T1, T2 and T3 in the four groups ( xˉ ±s)
Groups
Combined
therapy group
Lectroacupunct
ure group
ZZKZCgroup
Control group
T
T1
T2
T3
T1
T2
T3
T1
T2
T3
T1
T2
T3
n
120
120
120
120
120
120
120
120
120
120
120
120
Total times of
reflux
28.5±21.2
10.5±9.1abc
11.0±3.4defg
28.5±23.5
15.4±12.5ah
16.7±11.5di
28.5±13.4
15.4±10.4ah
19.7±14.4jk
28.5±23.7
15.5±12.6 a
19.7±25.5j
Times of
long-term
reflux
8.8±3.6
2.2±2.0abc
2.3±1.8defg
8.8±2.4
3.6±2.7ah
3.6±1.4 di
8.8±4.7
3.6±3.2ah
5.6±3.8jk
8.8±6.5
3.6±2.8a
5.6±2.3j
Percentage of
upright time
withAbs≥
0.14
19.8±5.7
3.3±3.8abc
3.2±2.2defg
19.8±12.5
5.4±4.0ah
5.4±3.8 di
19.8±17.5
5.4±2.3ah
8.5±5.3jk
19.8±11.4
5.4±4.7a
8.5±7.6j
Percentage of
supine time
withAbs≥
0.14
13.8±6.4
3.5±3.1abc
3.6±1.7defg
13.8±7.6
5.3±5.0ah
5.3±3.8 di
13.8±6.8
5.3±3.0 ah
7.5±6.9jk
13.8±5.3
5.2±4.7a
7.5±6.1j
Percentage of
total time
withAbs≥
0.14
18.0±3.6
3.6±2.4abc
3.6±2.2defg
18.0±13.6
5.4±1.4ah
5.4±4.9di
18.0±11.5
5.4±2.5ah
7.4±5.1jk
18.0±15.9
5.4±5.0a
7.4±3.8j
Notes:ComparedwiththesamegroupatT1,aP<0.01;ComparedwithcontrolgroupatT2,bP<0.05,hP>0.05;Comparedwithelectroacupunctureor
ZZKZCgroupatT2,cP<0.05;ComparedwiththesamegroupatT2,dP>0.05,jP<0.05;ComparedwithcontrolgroupatT3,eP<0.01,iP<0.05, kP>0.05;
Comparedwith electroacupuncture group atT3,fP<0.05;ComparedwithZZKZCgroup atT3,gP<0.01.
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Table 3 Comparison of the symptom scores and endoscopic grading scores at T1, T2and T3 in the four groups ( xˉ ±s)
Groups
Combined therapy
group
Electroacupuncture
group
ZZKZC group
Control group
T
T1
T2
T3
T1
T2
T3
T1
T2
T3
T1
T2
T3
n
120
120
120
120
120
120
120
120
120
120
120
120
Symptom score
19.51±8.25
4.55±3.74abc
4.56±2.63defg
19.50±7.82
6.88±4.73ah
6.91±3.75 di
19.51±7.46
6.87±3.61ah
9.74±3.63jk
19.50±3.80
6.86±3.35 a
9.73±4.68j
Endoscopic grading
score
3.28±0.52
0.36±0.14abc
0.38±0.17defg
3.27±1.64
0.59±0.23ah
0.61±0.46di
3.28±2.05
0.60±0.54ah
0.93±0.58jk
3.29±1.84
0.60±0.32 a
0.94±0.23j
Notes: Compared with the same group at T1, aP<0.01; Compared with control group at T2, bP<0.05, hP>0.05; Compared with
electroacupuncture or ZZKZC group at T2, cP<0.05; Compared with the same group at T2, dP>0.05, jP<0.05; Compared with control group
at T3, eP<0.01, iP<0.05, kP>0.05; Compared with electroacupuncture group at T3, fP<0.05; Compared with ZZKZC group at T3, gP<0.01.
Table 4 Comparison of the scores of 8 dimensions of quality of life at T1, T2and T3 in the four groups ( xˉ ±s)
Groups
Combined
therapy
group
Lectroacup
uncture
group
ZZKZC
group
Control
group
T
T1
T2
T3
T1
T2
T3
T1
T2
T3
T1
T2
T3
n
120
120
120
120
120
120
120
120
120
120
120
120
PF
81±23
95±15abc
94±23defg
81±37
88±13ah
87±32 di
81±24
87±16ah
84±20jk
81±26
87±13 a
84±26j
RP
44±14
88±31abc
87±16defg
44±25
68±39ah
67±13 di
44±23
67±15 ah
55±13jk
44±16
67±5a
55±21j
RE
56±18
85±14abc
85±24defg
54±14
73±6ah
72±36 di
54±18
73±24ah
64±35jk
54±43
74±16a
64±18j
SF
54±35
79±12abc
78±27defg
54±8
68±28ah
67±50 di
54±18
68±15ah
61±47jk
54±24
68±24a
61±14j
MH
57±18
80±16 abc
78±15defg
57±19
70±48 ah
69±12 di
57±32
71±30ah
65±18jk
57±26
70±18a
65±21j
VT
50±30
85±26abc
84±26defg
50±16
71±17 ah
71±23 di
50±48
71±20ah
63±20jk
51±37
71±38a
62±41j
BP
65±29
95±31abc
92±17defg
65±19
84±25ah
84±20 di
65±16
83±12ah
74±20jk
65±25
84±20a
74±50j
GH
54±19
86±35abc
85±505defg
54±15
75±18ah
75±27 di
54±22
75±16ah
67±34jk
54±11
75±18a
67±30j
Notes: Compared with the same group at T1, aP<0.01; Compared with control group at T2, bP<0.05, hP>0.05; Compared with
electroacupuncture or ZZKZC group at T2,cP<0.05; Compared with the same group at T2, dP>0.05, jP<0.05; Compared with control group
at T3, eP<0.01, iP<0.05, kP>0.05; Compared with electroacupuncture group at T3, fP<0.05; Compared with ZZKZC group at T3, gP<0.01.
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Table 5 Comparison of efficacy in the four groups [n (%)]
Groups
Combined therapy group
Electroacupuncture group
ZZKZC group
Control group
T
Short
Long
Short
Long
Short
Long
Short
Long
n
120
120
120
120
120
120
120
120
Marked efficacy
59(49.17)
58(48.33)
38(31.67)
38(31.67)
39(32.50)
32(26.67)
37(30.83)
31(25.83)
Efficacy
36(30.00)
34(28.33)
26(21.67)
25(20.83)
27(22.50)
20(16.67)
25(20.83)
25(20.83)
Improvement
21(17.50)
23(19.17)
33(27.50)
33(27.50)
31(25.83)
23(19.17)
34(28.33)
20(16.67)
Inefficacy
4(3.33)
5(4.17)
23(19.17)
24(20.00)
23(19.17)
45(37.50)
24(20.00)
44(36.67)
Total effective rate
116(96.67) ah
115(95.83) cjkf
97(80.83)b
96(80.00)ce
97(80.83)b
75(62.50) di
96(80.00)
76(63.33) d
Notes:Comparedwith the short-term efficacy of controlgroup,aP<0.05,bP>0.05; comparedwith the short-term efficacy of electroacupuncture
orZZKZCgrouphP<0.05; comparedwith the short-term efficacy of the same group cP>0.05, dP<0.05; compared with the long-term efficacy
of control group jP<0.01, eP<0.05, iP>0.05; compared with the long-term efficacy of electroacupuncture group kP<0.05; compared with the
long-term efficacy of ZZKZC group fP<0.01.
DISCUSSION
GERD is a frequently encountered illness induced by a
variety of causes of disease. It severely affects the quali-
ty of life of patients. Related drug abuse is common in
patients with GERD. Currently, the drugs used for
treatment of GERD mainly include acid inhibitors, an-
tiacids and gastrointestinal prokinetic agents. In treat-
ment of GERD, proton pump inhibitors have more ob-
vious advantages compared with other drugs, and have
attracted a lot of attention. Pantoprazole belongs to a
class of antisecretory compounds that can suppress gas-
tric acid secretion by inhibiting gastric H+/K+ATPase
at the secretory surface of gastric parietal cells, and this
is regarded as an acid (proton) pump within parietal
cells. Pantoprazole also suppresses gastric acid secretion
by exhibiting anticholinergic or histamine H2-receptor
antagonist properties. Pantoprazole is superior to other
acid inhibitors in inhibiting acid reflux, decreasing the
endoscopic grading score and alleviating reflux symp-
toms; therefore, it is a recommended drug for the treat-
ment of GERD.9 Mosapride is a derivative of benza-
mide and is a new type of kinetogenic drug for the
whole gastrointestinal tract, and it is also a strong selec-
tive 5-hydroxytryptamine4 (5-hydroxytryptamine4,
5-HT4) receptor activator. It can excite 5-HT 4 recep-
tors on cholinergic intermediary neurons and motor
neurons of the intermuscular plexus, increasing acetyl-
choline release of nerve endings and stimulating the ac-
tivity of myenteric nerves on cholinergic nerves. Mo-
sapride appears to promote gastrointestinal motor activ-
ity, it enhances esophageal and gastric emptying, and
intensifies the pressure of the lower segment sphincter,
to reduce reflux of gastro-duodenal content.10 There-
fore, the combination of pantoprazole with mosapride
markedly alleviates clinical symptoms of GERD, be-
cause the former significantly inhibits gastric acid, and
the latter can hasten gastric emptying. In our study, we
showed that after combined treatment of pantoprazole
and mosapride, intraesophageal acid and bile reflux,
the endoscopic grading score, symptoms of gastro-
esophageal reflux, and the quality of life were all signifi-
cantly improved. These findings indicate that this com-
bination inhibits intraesophageal acid and bile reflux,
decreases the endoscopic grading score, and alleviates
the symptoms of gastroesophageal reflux, to increase
the quality of life. However, 54 weeks after treatment,
we found that the above-mentioned detecting indexes
had recurred, suggesting recurrence after withdrawal,
which leads to poor long-term efficacy.
Because of the complex prescription containing Bai
Zhu (Atractylodes Macrocephala), Zhi Shi (Citrus Au-
rantium), Chai Hu (Bupleurum) and Shan Zha (haw-
thorn), ZZKZC is used to soothe Qi, harmonize Wei,
and depress the reverse flow of Qi, and has become the
preferred traditional Chinese medicine in gastrointesti-
nal motility. The results of our study showed that ZZ-
KZC had a notable short-term efficacy, but a poor
long-term efficacy, similar to routine Western medi-
cine, because of recurrence in symptoms after with-
drawal of treatment for gastroesophageal reflux disease.
Currently, Western medicine therapy often adopts
long-term maintenance treatment, but the cost is high
and adverse effects easily occur, so it is difficult for pa-
tient to accept the long-term maintenance treatment.
Therefore, the authors use traditional Chinese medi-
cine and acupuncture therapy for reducing recurrence
and the economic burden of patients.
According to the theory of traditional Chinese medi-
cine, GERD belongs to the category of "stomach
pain", "acid regurgitation", "epigastric upset", and
"fullness feeling". All of these are considered to be
caused by Qi-stagnation, Wei dysfunction, and an in-
verse rise in Qi. The therapeutic principle should be to
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disperse Qi, harmonize Wei, and depress the inversed
Qi. In acupuncture therapy, needling at the acupoints
of Zhongwan (CV 12), Zusanli (ST 36), and Neiguan
(PC 6) is regarded as an effective measure for moving
Qi to depress the inversion, and insertion of needles at
Sanyinjiao is known to be effective for dispersing
Gan-Qi to relieve pain. Combined together, they func-
tion to soothe Qi, harmonize Wei, and depress the re-
verse flow of Qi. The present study showed that after
treatment, the above-mentioned detecting indexes (in-
traesophageal acid and bile reflux, the endoscopic grad-
ing score, symptoms of gastroesophageal reflux, and
the quality of life) were all significantly improved in
the electroacupuncture and combination groups, and
54 weeks after treatment, these indices did not have a
significant recurrence, and had better long-term effica-
cy than ZZKZC and control groups.
The possible mechanism of acupuncture is as follows.
The signal produced by needling at Zusanli (ST 36) is
transmitted through the deep peroneal nerve and nerve
plexus on the anterior tibial arterial wall. This signal
congregates with sensory signals from the viscera (e.g.,
stomach and intestine) at different levels of the central
nervous system (spinal cord neurons, spinal dorsal
horn, and medulla oblongata) to create a special link
between Zang-Fu and Zusanli points and the acupoint
of Wei-Chang Meridian.
Previous studies have shown that acupuncture at Zu-
sanli (ST 36) can significantly increase gastro-kinetics,
increase electrogastrographic frequencies and promote
gastric emptying to improve gastric dyskinesis and de-
layed emptying. Moreover, acupuncture at Zusanli also
induces a notable change in gastro-intestinal hor-
mones. The level of motilin significantly increases after
needling, which can initiate a migrating kinematic
complex wave and increase the emptying of solids and
liquids from the stomach.11,12 At Zhongwan (CV 12),
the 7-11th intercostal nerves and superior epigastric ar-
tery and vein in the shallow layer are present..In addi-
tion, at CV 12, the pylorus and transverse colon lie in
the deeper layers, and in front of vertebral column, the
celiac plexus of the abdominal aorta and inferior vena
cava is found. A previous study found that needling at
CV 12 can increase the blood flow of the fundus to re-
duce effusion and thus protect the integrity of the gas-
tric membrane, inhibit the inverse diffusion of hydro-
gen ions, and decrease the net flow of Na+ and inhibit
gastric acid secretion.13
Therefore, it is speculated that acupuncture inhibits
gastric acid secretion and promotes gastro-enteric kinet-
ic. Acupuncture is beneficial to esophageal membrane
repair, without evident side effects or relapses. More-
over, the therapeutic effect of combining electroacu-
puncture and ZZKZC is more effective than either
alone, and therefore, this therapeutic treatment is ap-
propriate for clinical use.
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